AU2022264037A1 - Methods and compositions for treatment of diabetic retinopathy and related conditions - Google Patents

Methods and compositions for treatment of diabetic retinopathy and related conditions Download PDF

Info

Publication number
AU2022264037A1
AU2022264037A1 AU2022264037A AU2022264037A AU2022264037A1 AU 2022264037 A1 AU2022264037 A1 AU 2022264037A1 AU 2022264037 A AU2022264037 A AU 2022264037A AU 2022264037 A AU2022264037 A AU 2022264037A AU 2022264037 A1 AU2022264037 A1 AU 2022264037A1
Authority
AU
Australia
Prior art keywords
therapeutic agent
patient
orally administered
certain embodiments
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022264037A
Other languages
English (en)
Inventor
Mitchell George BRIGELL
Konstantinos Charizanis
Mark R. Kelley
Richard Adam Messmann
Ronil Ajaykumar PATEL
Mina SOOCH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opus Genetics Inc
Original Assignee
Opus Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opus Genetics Inc filed Critical Opus Genetics Inc
Publication of AU2022264037A1 publication Critical patent/AU2022264037A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022264037A 2021-04-30 2022-04-29 Methods and compositions for treatment of diabetic retinopathy and related conditions Pending AU2022264037A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182037P 2021-04-30 2021-04-30
US63/182,037 2021-04-30
PCT/US2022/027062 WO2022232597A1 (en) 2021-04-30 2022-04-29 Methods and compositions for treatment of diabetic retinopathy and related conditions

Publications (1)

Publication Number Publication Date
AU2022264037A1 true AU2022264037A1 (en) 2023-11-16

Family

ID=83848745

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022264037A Pending AU2022264037A1 (en) 2021-04-30 2022-04-29 Methods and compositions for treatment of diabetic retinopathy and related conditions

Country Status (11)

Country Link
US (1) US20240216315A1 (cg-RX-API-DMAC7.html)
EP (1) EP4329741A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024516003A (cg-RX-API-DMAC7.html)
KR (1) KR20240049212A (cg-RX-API-DMAC7.html)
CN (1) CN117500492A (cg-RX-API-DMAC7.html)
AU (1) AU2022264037A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022561A2 (cg-RX-API-DMAC7.html)
CA (1) CA3217136A1 (cg-RX-API-DMAC7.html)
IL (1) IL308083A (cg-RX-API-DMAC7.html)
MX (1) MX2023012793A (cg-RX-API-DMAC7.html)
WO (1) WO2022232597A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025529483A (ja) 2022-09-14 2025-09-04 オーパス・ジェネティクス・インコーポレイテッド Apx3330の塩及びエステルならびにその治療的使用
WO2024158972A1 (en) * 2023-01-25 2024-08-02 Ocuphire Pharma, Inc. Methods and compositions for preventing the progression of diabetic retinopathy and related conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0817293A2 (pt) * 2007-09-26 2015-06-16 Univ Indiana Res & Tech Corp Derivado de benzoquinona e3330 em combinação com agentes quimioterapêuticos para o tratamento de câncer e angiogenese
CA3090766A1 (en) * 2018-02-08 2019-08-15 Indiana University Research And Technology Corporation Targeting ocular diseases with novel ape1/ref-1 inhibitors

Also Published As

Publication number Publication date
WO2022232597A1 (en) 2022-11-03
JP2024516003A (ja) 2024-04-11
BR112023022561A2 (pt) 2024-01-02
MX2023012793A (es) 2024-01-11
US20240216315A1 (en) 2024-07-04
KR20240049212A (ko) 2024-04-16
EP4329741A1 (en) 2024-03-06
CA3217136A1 (en) 2022-11-03
IL308083A (en) 2023-12-01
EP4329741A4 (en) 2025-01-08
CN117500492A (zh) 2024-02-02

Similar Documents

Publication Publication Date Title
JP7774170B2 (ja) 翼状片を治療するための組成物及び方法
JP5341933B2 (ja) 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
JP7116490B2 (ja) 眼の炎症性障害および疾患の組合せ処置
EP2524693B1 (en) Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability
KR20040100844A (ko) 눈에 국소적으로 사용하기 위한 브리모니딘과 티몰롤의조합물
US11723890B2 (en) Methods of treatment using an mTORC1 modulator
UA103592C2 (uk) Застосування тестостерону і агоніста 5-нт1а для лікування сексуальної дисфункції
CN119745879A (zh) 包含阿西替尼的组合物和治疗眼部疾病的方法
US20240216315A1 (en) Methods and compositions for treatment of diabetic retinopathy and related conditions
AU2024204716A1 (en) Treatment of alopecia areata
US20050043220A1 (en) Methods and compositions for treating macular degeneration
US20240148709A1 (en) Methods of treating eye pain and eye disorders
WO2025072687A1 (en) Methods and compositions for treatment of geographic atrophy
US20240252497A1 (en) Use of complement factor d inhibitor for treatment of geographic atrophy secondary to age-related macular degeneration
US20260108483A1 (en) Methods and compositions for preventing the progression of diabetic retinopathy and related conditions
KR101387988B1 (ko) 맨틀 세포 림프종 치료용 cci-779
HK40101374A (en) Compositions and methods for treating pterygium
US20080234351A1 (en) Combination Methods for Preserving Visual Acuity
WO2024211216A1 (en) Cilnidipine and a p-glycoprotein inhibitor for treating pain
HK1253895B (en) Compositions and methods for treating pterygium

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANTS TO OPUS GENETICS, INC.